Literature DB >> 10052695

Determination of a cyclic hexapeptide, a novel antifungal agent, in human plasma by high-performance liquid chromatography with ion spray and turbo ion spray tandem mass spectrometric detection.

C M Chavez-Eng1, M Schwartz, M L Constanzer, B K Matuszewski.   

Abstract

Methods for the determination of a semi-synthetic cyclic hexapeptide (I, MK-0991) in human plasma based on high-performance liquid chromatography (HPLC) with tandem mass spectrometric (MS-MS) detection using pneumatically assisted electrospray (ion spray, ISP) and turbo ion spray (TISP) interfaces were developed. Drug and internal standard (II, an isostere of I) were isolated from plasma by solid-phase extraction (SPE). The eluent from SPE was evaporated to dryness, the residue was reconstituted in mobile phase and injected into the HPLC system. The use of ISP, TISP and heated nebulizer (HN) interfaces as sample introduction systems were evaluated and showed that the heated nebulizer was not adequate for analysis due to thermal instability and/or adsorption of I and II to glass surfaces of the interface. Compounds I and II were chromatographed on a wide pore (300 A), 150x4.6 mm C8 analytical column, and the HPLC flow-rate of 1.2 ml/min was split 1:20 prior to introduction to the ISP or TISP interface of the mass spectrometric system. The MS-MS detection was performed on a PE Sciex API III Plus tandem mass spectrometer operated in selected reaction monitoring mode (SRM). The precursor-->product ion combinations of m/z 1093.7-->1033.6 and 1094.7-->1033.6 were used to quantify I and II, respectively, after chromatographic separation of the analytes. The assay was validated in the concentration range of 10-1000 ng/ml using ISP, and 2.5-500 ng/ml of plasma using TISP with good precision and adequate accuracy. The effects of HPLC mobile-phase components on the ionization efficiency and sensitivity of detection in the positive ionization mode, the evaluation of the matrix effect, and limitations in sensitivity of detection of I due to the formation of multiply charged species are presented.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10052695     DOI: 10.1016/s0378-4347(98)00447-2

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  5 in total

1.  Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin.

Authors:  Laurent Arthur Decosterd; Bertrand Rochat; Benoît Pesse; Thomas Mercier; Frédéric Tissot; Nicolas Widmer; Jacques Bille; Thierry Calandra; Boris Zanolari; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

2.  Rapid and sensitive liquid chromatography/mass spectrometry assay for caspofungin in human aqueous humor.

Authors:  Chin Fen Neoh; Hui He; Jian Li; Robert O Fullinfaw; Lok Leung; Anant Misra; Rasik B Vajpayee; Geoffrey E Davies; Kay Stewart; David C M Kong
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

3.  Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry.

Authors:  Fedja Farowski; Oliver A Cornely; Jörg J Vehreschild; Pia Hartmann; Tim Bauer; Angela Steinbach; Maria J G T Rüping; Carsten Müller
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

4.  Effect of the echinocandin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitro.

Authors:  Jean-Sébastien Ripeau; Francine Aumont; Pierre Belhumeur; Luis Ostrosky-Zeichner; John H Rex; Louis de Repentigny
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

5.  Ocular penetration of caspofungin in a rabbit uveitis model.

Authors:  David Goldblum; Kathrin Fausch; Beatrice E Frueh; Regula Theurillat; Wolfgang Thormann; Stefan Zimmerli
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-22       Impact factor: 3.535

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.